Christoph Meisner - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Christoph Meisner

Showing results (91-100 of 100) with videos related to

Pageof 10

Sort By:

You have reached the last page of results.This site can display upto 100 results.

Neuro-Oncology|February 18, 2020

Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytomaAntje Wick, Tobias Kessler, Michael Platten, et al.

Neuro-Oncology|April 19, 2013

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collectiveBenedikt Wiestler, Rainer Claus, Sabine A Hartlieb, et al.

International Journal of Stroke : Official Journal of the International Stroke Society|November 25, 2016

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study designTobias Geisler, Sven Poli, Christoph Meisner, et al.

NEJM Evidence|February 6, 2024

High-Dose Glucocorticoids for the Treatment of Sudden Hearing LossStefan K Plontke, Matthias Girndt, Christoph Meisner, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 25, 2013

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapyMarkus Weiler, Jonas Blaes, Stefan Pusch, et al.

Nature|November 23, 2021

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.

Oncotarget|November 24, 2016

Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.

Leukemia|August 30, 2019

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.

Brain : a Journal of Neurology|November 11, 2017

Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trialLudger Schöls, Tim W Rattay, Peter Martus, et al.

Nature Communications|August 18, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyJonas S Heitmann, Claudia Tandler, Maddalena Marconato, et al.

Pageof 10

Search research articles

Showing results (91-100 of 100) with videos related to

Sort By:

Pageof 10

You have reached the last page of results.This site can display upto 100 results.

Neuro-Oncology|February 18, 2020

Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytomaAntje Wick, Tobias Kessler, Michael Platten, et al.

Neuro-Oncology|April 19, 2013

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collectiveBenedikt Wiestler, Rainer Claus, Sabine A Hartlieb, et al.

International Journal of Stroke : Official Journal of the International Stroke Society|November 25, 2016

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study designTobias Geisler, Sven Poli, Christoph Meisner, et al.

NEJM Evidence|February 6, 2024

High-Dose Glucocorticoids for the Treatment of Sudden Hearing LossStefan K Plontke, Matthias Girndt, Christoph Meisner, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 25, 2013

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapyMarkus Weiler, Jonas Blaes, Stefan Pusch, et al.

Nature|November 23, 2021

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunityJonas S Heitmann, Tatjana Bilich, Claudia Tandler, et al.

Oncotarget|November 24, 2016

Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.

Leukemia|August 30, 2019

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.

Brain : a Journal of Neurology|November 11, 2017

Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trialLudger Schöls, Tim W Rattay, Peter Martus, et al.

Nature Communications|August 18, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyJonas S Heitmann, Claudia Tandler, Maddalena Marconato, et al.

Pageof 10